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Obesity is defined as the abnormal or excessive accumulation of total body fat that is 
reported as having a BMI of more than 30kg/m2.[1] The genesis of obesity is complex that is 
a result due to the imbalance in the energy intake and energy expenditure.  
Obesity is known to be associated with other metabolic co-morbidities and is an important 
risk factor for cardiovascular diseases (CVD) including endothelial dysfunction. Obesity is 
an important predictor of CVD, which begins when several risk factors, including lipid 
abnormalities, high blood pressure, impaired glucose tolerance, proinflammatory and pro-
thrombotic states co-exist in obese individuals, which in turn induce endothelial 
dysfunction. Endothelial dysfunction (ED) is 
defined as the imbalance between 
vasoconstrictors and vasodilators produced 
by and acting on the endothelium leading to 
loss or impairment of its physiological 
properties.[2] Vascular endothelium has a vital 
role in the maintenance of cardiovascular 
homeostasis in health. The endothelium, 
although a simple monolayer, apart from 
acting as a physical barrier between the 
vessel wall and lumen, responds to physical 
and chemical signals by secreting a wide 
range of mediators that regulate platelet 
aggregation, coagulation, fibrinolysis and 
vessel tone.  
During obesity, the vascular homeostasis is 
disrupted due to elevated blood pressure 
levels and loss of vascular tone. A key 
signaling molecule is nitric oxide (NO) that 
is produced endogenously. In mammals, NO 
is synthesized from L-arginine by the 
enzyme NO Synthases (NOS) that is 
available in three isoforms: neuronal NOS 
(nNOS), inducible NOS (iNOS) and 
endothelial NOS (eNOS). eNOS is most 
abundant in the vascular endothelium 
which generates NO by the NADPH- and O2-dependent oxidation of L-arginine to L-citrulline 
in the presence of the endothelial cofactor, tetrahydrobiopterin (BH4).[3] An endogenous 
competitive inhibitor of eNOS is asymmetric dimethyl arginine (ADMA) which inhibits NO 
synthesis by competing with L-arginine at the active site of eNOS. It has been hypothesized 
that ADMA may play a direct role in the dysregulation of L-arginine/NO pathway. [4] 
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Fig. 4: Distribution of CAF-fed rats at week 16. CAF-fed rats exhibited greater to-
tal weight gain when compared to NC wherein 44% of the CAF-fed group gained 
30% more from their initial weight while the remaining 56% were found to be re-
sistant to weight gain and were similar to the NC group .  
Fig. 5: The plasma glucose concentrations between the groups. There was no 
significant difference between the weight resistant group (CAF-WR) and obese 
group (CAF-OB) when compared to their control counterparts. 
Obesity has been recognized as a pandemic and linked with several metabolic dysfunctions. One of the hallmarks in the onset of obesity is the development of hypertension coupled with endothelial dysfunction. (ED) A fundamental feature of ED is the reduced 
bioavailability of the key vasodilator, nitric oxide (NO), which has important vasoactive functions. Endothelial nitric oxide is significantly produced by the isoform endothelial nitric oxide synthase (eNOS) in the vascular wall. NO production is modulated by both 
physiological and pathophysiological environment. Several recent studies have reported the correlation of obesity with NO bioavailability and the endogenous inhibitor of eNOS, asymmetric dimethyl arginine (ADMA).  This research aims to define the 
mechanisms that contribute to controlling eNOS activity and NO bioavailability during obesity conditions. In this study, eight week-old male Sprague-Dawley rats were exposed to cafeteria diet for 16 weeks. Our findings show that body weight increased 
gradually with 44% of the CAF-fed group becoming obese (CAF-OB) and the remaining 56% becoming resistant to body weight gain (CAF-WR). Levels of plasma ADMA increased and serum nitrite concentrations were reduced in the CAF-OB group while the 
CAF-WR group had a decrease in plasma ADMA levels and an increase in serum nitrite concentrations. This reflects the interaction of ADMA as an endogenous inhibitor on the bioavailability of NO. In conclusion, CAF diet induces obesogenic effects leading to 
endothelial dysfunction in both weight gain and weight gain resistant groups. 
Fig. 1: Global estimates of obesity 
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Fig. 3: Weekly body weight gain in male SD rats. CAF-fed rats exhibited signifi-
cant weight gain after one week and persisted throughout the study reaching al-
most twice the weight compared to the control group with P-value ≤ 0.01. Interest-
ingly, this study also reports a finding wherein some of the CAF diet fed rats resist-
ed weight gain.  
 
Rats exposed to the CAF diet exhibited an initial high intake of the diet repre-
senting hyperphagia as well as reflecting the palatability and preference of the 
CAF diet over standard chow. Our findings are in agreement with studies show-
ing that exposure to CAF diet induces hyperphagia[5], leading to increased 
weight gain in less than half of the population[6] while the others become re-
sistant to weight gain[7].  
This study demonstrated that high consumption of CAF diet resulted in high weight 
gain and diet induced obesity resembling the patterns of human obesity. This pattern 
of obesity was not associated with significant increase in blood glucose levels yet the 
serum levels of endogenous inhibitor, ADMA increased above basal levels that might 
result in endothelial dysfunction and reduced NO production and bioavailability as 
explained by the serum levels of nitrite.  
Interestingly, these changes were detected for the first time in weight gain resistant 
group that needs further investigation to understand pathophysiology of high-energy 
consumption and impairment of NO production and bioavailability under non-obese 
conditions. 
Regardless of the weight gain and availability of the standard chow, rats contin-
ued to consume the energy dense CAF diet in excessive amounts revealing that 
weight gain was not associated with high glucose levels. This indicates that hy-
perglycemia was not detected and the rats are in the early stages to a diabetic 
condition. 
Fig. 2: Synthesis of nitric oxide 
Undergraduate Student, Sciences & Engineering 
Determination of ADMA in plasma 
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Fig. 8 & 9: Concentration of ADMA by ELISA. ADMA levels increased in obese rats 
when compared to their control counterparts. The CAF-WR group shows a slight de-
crease in the ADMA concentrations while the  CAF-OB group shows an increase in AD-
MA concentrations  relative to the NC group. 
 
CAF diet induced obesity stimulates ADMA increase coupled with decreased NO.  
However, ED is detectable and manifested after the onset of hyperglycemia.[9] 
Determination of NOx bioavailability as nitrite in serum 
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Fig. 6 & 7: Chemical reduction by Griess’ reaction  to determine the level of 
nitrite. Although the level of nitrite in CAF-OB group did not show statistical sig-
nificance, the values of concentration of nitrite was diminished in CAF-OB group. 
Interestingly, there was an increase in the CAF-WR group yet it did not show statis-
tical difference in comparison to NC group.  
It has been hypothesized that the unaltered plasma NO levels due to CAF diet 
may be due to the inhibition of arginine production thus preventing the increase 
of NO production under CAF diet induced obesity. [8] 
Evaluation of vasodilation response as blood pressure 
Initial BP (mmHg) Final BP (mmHg) 
Group   
Systolic Diastolic Systolic Diastolic 
NC 166.8±5.5 134.7±5.6 148.8±4.5 106.3±3.9 
CAF-OB 161.2±6.3 123.9±6.5 166.4±4.9 119.0±4.7 
CAF-WR 168.3±7.2 129.1±7.1 157.7±3.6 111.1±4.4 
Table 1: Blood pressure of male SD rats. Our investigation reveals a significant drop 
in the blood pressure in both control and CAF-fed groups while being within range as 
published by other research group.   
This drop in blood pressure could be due to the fact that the evaluated parameters of 
endothelial cell function have not deteriorated to reflect the significant changes. It 
has been reported that the L-arginine/ADMA ratio has a negative correlation with 
systolic blood pressure. [9] 
